MAPK6 · Western blot design guide

MAPK6 Western Blot Planning Guide

Plan a MAPK6 Western blot around the catalog-observed 82.7 kDa band, image-backed PB9666 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for MAPK6 (MAPK6): expected band 82.7 kDa, antibody PB9666, and guide-derived SDS-PAGE protocol steps
MAPK6 Western blot protocol sheet — expected band 82.7 kDa, antibody PB9666, controls and PMC citations. Open the full MAPK6 WB guide →

MAPK6 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 82.7 kDa
Observed band Not reported — verify product WB image
Gel 8-10%
Positive control ⓘ Cerebellum
Negative control ⓘ Oral mucosa
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 82.7 kDa
ⓘ Localization Cytoplasm / Nucleus
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated MAPK6 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateBreast
Gel %8-10%
Load20-30 µg total protein per lane
TransferSemi-dry, standard transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryPB9666 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected MAPK6 Western Blot Band Size?

Use the product-observed 82.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
82.7 kDaMatches the authoritative product WB observation.
82.7 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected MAPK6 appearancePlan around 82.7 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band82.7 kDa; use this as the primary experimental expectation.
Calculated mass82.7 kDa from UniProt Q16659; retain as context.
Gel selection8-10%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with PB9666.
Why is my band missing or off?
SituationLikely causeNext action
82.7 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for MAPK6 Western blot

🧪Use Cerebellum as the first positive-control candidate and Oral mucosa as the HPA Not detected negative candidate.
Positive control: Cerebellum (High)
Negative control: Oral mucosa (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for MAPK6

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Cerebellum Reported tissue cells High Protein (HPA) HPA →
Breast Reported tissue cells High Protein (HPA) HPA →
Kidney Reported tissue cells High Protein (HPA) HPA →
Duodenum Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Oral mucosa Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced MAPK6 Western Blot Tips

Deeper troubleshooting and optimisation questions for MAPK6, answered from its protein features.

Which band should guide the blot?
Use 82.7 kDa, the observation attached to the authoritative PB9666 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 82.7 kDa expectation.
Which positive control should I start with?
Start with Cerebellum, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Oral mucosa as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for MAPK6 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9666 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

MAPK6 Western Blot Reagents

Human/Mouse/Rat-reactive MAPK6 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for MAPK6 using PB9666; observed band 82.7 kDa
Anti-MAPK6 Antibody Picoband®
Cat # PB9666

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt Q16659
  2. Human Protein Atlas — MAPK6
  3. PB9666 product record
  4. PMC4207808 — Up-regulated microRNA499a by hepatitis B virus induced hepatocellular carcinogenesis via targeting MAPK6 (PloS one, 2014)
  5. PMC4805855 — Substrate-Trapped Interactors of PHD3 and FIH Cluster in Distinct Signaling Pathways (Cell reports, 2016)
  6. PMC7476952 — Knockdown of long non-coding RNA TTTY15 protects cardiomyocytes from hypoxia-induced injury by regulating let-7b/MAPK6 axis (International journal of clinical and experimental pathology, 2020)